Industry

Hyundai Card Becomes First in Asia to Achieve UL Solutions Healthy Building Verifications for Cultural and Leisure Facilities

Four iconic Hyundai Card structures earn the UL Verified Healthy Building Mark, demonstrating Hyundai Card’s commitment to creating healthier and more sustainable indoor environments for employees and guests. NORTHBROOK, Ill.–(BUSINESS WIRE)–UL Solutions (NYSE: ULS), a global leader in applied safety science, today announced that four properties operated by Hyundai Card, a leading South Korean credit … [Read more…]

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support … [Read more…]

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting … [Read more…]

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free … [Read more…]

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary … [Read more…]

ConcertAI Provides Intelligent Automation of ASCO® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ® SmartLinQ™ Solutions

Powered by CARAai, ASCO® Guideline-concordant care recommendations will be automatically provided to CancerLinQ Network medical oncologists through SmartLinQ, and for biopharma research through Precision Explorer and Trials CAMBRIDGE, Mass.–(BUSINESS WIRE)–ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the … [Read more…]

EDS Service Solutions Named a 2025 Georgia Fast 40 Honoree by ACG Atlanta for Third Year in a Row

ATLANTA–(BUSINESS WIRE)–#CarRentalIndustry–EDS Service Solutions, a national provider of labor outsourcing and workforce management services across the travel, hospitality, logistics, automotive and aviation industries, has been named a 2025 Georgia Fast 40 honoree by the Atlanta chapter of the Association for Corporate Growth. According to ACG Atlanta, the Georgia Fast 40 program recognizes the top 40 … [Read more…]

CORRECTING and REPLACING New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, with a 31% reduction in the risk of progression or death compared to enzalutamide alone (HR 0.69; 95% CI, 0.54-0.87; p=0.0009) At the pre-planned interim analysis, patients treated with XOFIGO in … [Read more…]

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025 VANCOUVER, British Columbia–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial … [Read more…]

Cofactor Genomics Presents Breakthrough Work Combining RNA and AI to bring Precision Medicine to Immunotherapy at RNA Society’s 30th Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–Cofactor Genomics announced the latest validation results for OncoPrism®, Cofactor’s breakthrough RNA-based diagnostic approach at the RNA Society’s 30th Annual Meeting. The talk, presented by Dr. Kevin Flanagan (Cofactor’s VP of Translational Science), “Bringing Precision Medicine to Cancer Immunotherapy with a Robust RNA Diagnostic Platform”, highlighted OncoPrism’s dramatic improvement in the prediction of … [Read more…]